Soukup A, Meier V, Pot S, Voelter K, Rohrer Bley C
Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Division of Ophthalmology, Equine Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Vet Comp Oncol. 2018 Dec;16(4):441-449. doi: 10.1111/vco.12399. Epub 2018 May 14.
In order to overcome the common local treatment failure of canine sinonasal tumours, integrated boost techniques were tried in the cobalt/orthovoltage era, but dismissed because of unacceptable early (acute) toxicity. Intriguingly, a recent calculation study of a simultaneously integrated boost (SIB) technique for sinonasal irradiation using intensity-modulated radiation therapy (IMRT) predicted theoretical feasibility. In this prospective pilot study we applied a commonly used protocol of 10 × 4.2 Gy to the planning target volume (PTV) with a 20%-SIB dose to the gross tumour volume (GTV). Our hypothesis expected this dose escalation to be clinically tolerable if applied with image-guided IMRT. We included 9 dogs diagnosed with sinonasal tumours without local/distant metastases. For treatment planning, organs at risk were contoured according to strict anatomical guidelines. Planning volume extensions (GTV/CTV/PTV) were standardized to minimize interplanner variability. Treatments were applied with rigid patient positioning and verified daily with image guidance. After radiation therapy, we set focus on early ophthalmologic complications as well as mucosal and cutaneous toxicity. Early toxicity was evaluated at week 1, 2, 3, 8 and 12 after radiotherapy. Only mild ophthalmologic complications were found. Three patients (33%) had self-limiting moderate to severe early toxicity (grade 3 mucositis) which was managed medically. No patient developed ulcerations/haemorrhage/necrosis of skin/mucosa. The SIB protocol applied with image-guided IMRT to treat canine sinonasal tumours led to clinically acceptable side effects. The suspected increased tumour control probability and the risk of late toxicity with the used dose escalation of 20% has to be further investigated.
为了克服犬鼻窦肿瘤常见的局部治疗失败问题,在钴/正交电压放疗时代尝试了综合加量技术,但由于不可接受的早期(急性)毒性而被摒弃。有趣的是,最近一项关于使用调强放射治疗(IMRT)对鼻窦进行同步整合加量(SIB)技术的计算研究预测了理论可行性。在这项前瞻性试点研究中,我们对计划靶区(PTV)应用了常用的10×4.2 Gy方案,并对大体肿瘤体积(GTV)给予20%的SIB剂量。我们的假设预期,如果采用图像引导的IMRT应用这种剂量递增,在临床上是可耐受的。我们纳入了9只被诊断为鼻窦肿瘤且无局部/远处转移的犬。为进行治疗计划,根据严格的解剖学指南勾勒出危及器官。计划体积扩展(GTV/CTV/PTV)进行了标准化,以尽量减少计划者之间的差异。治疗时患者体位固定,并每天通过图像引导进行验证。放疗后,我们重点关注早期眼科并发症以及黏膜和皮肤毒性。在放疗后第1、2、3、8和12周评估早期毒性。仅发现轻度眼科并发症。3例患者(33%)出现自限性的中度至重度早期毒性(3级黏膜炎),经药物治疗。没有患者出现皮肤/黏膜溃疡/出血/坏死。采用图像引导的IMRT应用SIB方案治疗犬鼻窦肿瘤导致临床上可接受的副作用。所怀疑的使用20%剂量递增后肿瘤控制概率增加以及晚期毒性风险必须进一步研究。